These results demonstrate, for the first time, that MRI deltaPO2 detects a significant supernormal retinal oxygenation response in patients with type I diabetes, even before the appearance of retinopathy. This study raises the possibility of using MRI measurements of deltaPO2 to monitor therapeutic efficacy in human trials.